Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 23500197)

1.

Non-psychotropic analgesic drugs from the endocannabinoid system: "magic bullet" or "multiple-target" strategies?

Starowicz K, Di Marzo V.

Eur J Pharmacol. 2013 Sep 15;716(1-3):41-53. doi: 10.1016/j.ejphar.2013.01.075. Epub 2013 Mar 13. Review.

PMID:
23500197
2.

Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.

Anand P, Whiteside G, Fowler CJ, Hohmann AG.

Brain Res Rev. 2009 Apr;60(1):255-66. doi: 10.1016/j.brainresrev.2008.12.003. Epub 2008 Dec 25. Review.

PMID:
19150370
3.

"Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control.

Piscitelli F, Di Marzo V.

ACS Chem Neurosci. 2012 May 16;3(5):356-63. doi: 10.1021/cn300015x. Epub 2012 Feb 27. Review.

4.

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.

Petrosino S, Di Marzo V.

Curr Opin Investig Drugs. 2010 Jan;11(1):51-62. Review.

PMID:
20047159
5.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

6.

Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy.

Rice AS, Farquhar-Smith WP, Nagy I.

Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):243-56. Review.

PMID:
12052040
7.

Endocannabinoids: a unique opportunity to develop multitarget analgesics.

Maione S, Costa B, Di Marzo V.

Pain. 2013 Dec;154 Suppl 1:S87-93. doi: 10.1016/j.pain.2013.03.023. Epub 2013 Mar 15. Review.

PMID:
23623250
8.

[The cannabinoid system and pain: towards new drugs?].

Beltramo M.

J Soc Biol. 2009;203(1):99-106. doi: 10.1051/jbio:2009002. Epub 2009 Apr 10. Review. French.

PMID:
19358815
9.

Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.

Burns TL, Ineck JR.

Ann Pharmacother. 2006 Feb;40(2):251-60. Epub 2006 Jan 31. Review.

PMID:
16449552
10.

Therapeutic potential of cannabinoids in CNS disease.

Croxford JL.

CNS Drugs. 2003;17(3):179-202. Review.

PMID:
12617697
11.

Cannabinoid receptors and pain.

Pertwee RG.

Prog Neurobiol. 2001 Apr;63(5):569-611. Review.

PMID:
11164622
12.

Endocannabinoid system and mood disorders: priming a target for new therapies.

Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F.

Pharmacol Ther. 2013 Apr;138(1):18-37. doi: 10.1016/j.pharmthera.2012.12.002. Epub 2012 Dec 20. Review.

PMID:
23261685
13.

Cannabis and cannabinoids: pharmacology and rationale for clinical use.

Pertwee RG.

Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. Review.

PMID:
10575283
14.

At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction.

Montecucco F, Di Marzo V.

Trends Pharmacol Sci. 2012 Jun;33(6):331-40. doi: 10.1016/j.tips.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503477
15.

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

Di Marzo V.

Pharmacol Res. 2009 Aug;60(2):77-84. doi: 10.1016/j.phrs.2009.02.010. Epub 2009 Mar 4. Review.

PMID:
19559360
16.

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.

Mitchell VA, Greenwood R, Jayamanne A, Vaughan CW.

Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1186-90.

PMID:
17880375
17.

The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.

Chicca A, Marazzi J, Gertsch J.

Br J Pharmacol. 2012 Dec;167(8):1596-608. doi: 10.1111/j.1476-5381.2012.02059.x.

18.

[The role of endocannabinoid system in physiological and pathological processes in the eye].

Nadolska K, Goś R.

Klin Oczna. 2008;110(10-12):392-6. Review. Polish.

PMID:
19195174
19.

The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation.

Alvarez-Jaimes LJ, Palmer JA.

Curr Pharm Biotechnol. 2011 Oct;12(10):1644-59. Review.

PMID:
21466449
20.

Gut feelings about the endocannabinoid system.

Di Marzo V, Piscitelli F.

Neurogastroenterol Motil. 2011 May;23(5):391-8. doi: 10.1111/j.1365-2982.2011.01689.x.

PMID:
21481098
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk